Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

You are here: Home / Biomarkers / VEGFA



This biomarker is also known as:
  • vascular endothelial growth factor,
  • MVCD1,
  • VEGF,
  • VPF,
  • VEGF-A,
  • Vascular permeability factor,
  • vascular endothelial growth factor A,


Vascular endothelial growth factor (VEGFA or VEGF) is a growth factor and signaling protein involved in the regulation of angiogenesis, vasculogenesis, and endothelial cell grown. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Three VEGFR isoforms have been identified in humans; VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR-2 mediates the majority of cellular responses to VEGF. VEGFR-1 is thought to modulate VEGFR-2 signaling or to act as a dummy/decoy receptor to sequester VEGF away from VEGFR-2.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


Preclinical and clinical studies have suggested that VEGFA is important in human breast cancer.

Performance Comment

VEGFA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.



Phase: Two
QA State: Under Review


Elevated levels of VEGFA in serum and tumor tissue are associated with poor prognosis in patients with lung cancer.

Performance Comment

Levels of angiogenic markers FGF2, ANG, and VEGFA in exhaled breath condensate significantly discriminated between 17 individuals with newly detected non-small cell lung cancer versus stable and exacerbated chronic obstructive pulmonary disease (COPD).


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


Mutation Statistics

Gene Name: VEGFA
UniProt Accession #: P15692
Mutated Sites Count: 86
Associated Pubmed ID Count 5
CancerDO Count 17
Affected Protein Function Sites Count: 1

View in BioMuta